257 related articles for article (PubMed ID: 20197139)
1. Stability and potency of the Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate with Montanide ISA720 adjuvant.
Xue X; Ding F; Zhang Q; Pan X; Qu L; Pan W
Vaccine; 2010 Apr; 28(18):3152-8. PubMed ID: 20197139
[TBL] [Abstract][Full Text] [Related]
2. A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant.
Saul A; Lawrence G; Allworth A; Elliott S; Anderson K; Rzepczyk C; Martin LB; Taylor D; Eisen DP; Irving DO; Pye D; Crewther PE; Hodder AN; Murphy VJ; Anders RF
Vaccine; 2005 Apr; 23(23):3076-83. PubMed ID: 15811655
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
Lalitha PV; Biswas S; Pillai CR; Saxena RK
Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
[TBL] [Abstract][Full Text] [Related]
5. Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth.
Bruder JT; Stefaniak ME; Patterson NB; Chen P; Konovalova S; Limbach K; Campo JJ; Ettyreddy D; Li S; Dubovsky F; Richie TL; King CR; Long CA; Doolan DL
Vaccine; 2010 Apr; 28(18):3201-10. PubMed ID: 20188680
[TBL] [Abstract][Full Text] [Related]
6. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium.
Bargieri DY; Leite JA; Lopes SC; Sbrogio-Almeida ME; Braga CJ; Ferreira LC; Soares IS; Costa FT; Rodrigues MM
Vaccine; 2010 Apr; 28(16):2818-26. PubMed ID: 20170765
[TBL] [Abstract][Full Text] [Related]
7. Fusion of two malaria vaccine candidate antigens enhances product yield, immunogenicity, and antibody-mediated inhibition of parasite growth in vitro.
Pan W; Huang D; Zhang Q; Qu L; Zhang D; Zhang X; Xue X; Qian F
J Immunol; 2004 May; 172(10):6167-74. PubMed ID: 15128804
[TBL] [Abstract][Full Text] [Related]
8. [Influence of deleting 9 amino acid residues at N-terminus on immunogenicity of a Plasmodium falciparum chimeric protein].
Zhang QF; Pan WQ; Qu L; Xue XY
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Apr; 35(4):345-9. PubMed ID: 12673388
[TBL] [Abstract][Full Text] [Related]
9. Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice.
Jeamwattanalert P; Mahakunkijcharoen Y; Kittigul L; Mahannop P; Pichyangkul S; Hirunpetcharat C
Clin Vaccine Immunol; 2007 Apr; 14(4):342-7. PubMed ID: 17314232
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice.
Mata E; Carcaboso AM; Hernández RM; Igartua M; Corradin G; Pedraz JL
Vaccine; 2007 Jan; 25(5):877-85. PubMed ID: 17070628
[TBL] [Abstract][Full Text] [Related]
11. Solution structure of a Plasmodium falciparum AMA-1/MSP 1 chimeric protein vaccine candidate (PfCP-2.9) for malaria.
Peng H; Hu Y; Zhou A; Jin C; Pan W
Malar J; 2010 Mar; 9():76. PubMed ID: 20236549
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in montanide ISA 720 in healthy adults.
Hu J; Chen Z; Gu J; Wan M; Shen Q; Kieny MP; He J; Li Z; Zhang Q; Reed ZH; Zhu Y; Li W; Cao Y; Qu L; Cao Z; Wang Q; Liu H; Pan X; Huang X; Zhang D; Xue X; Pan W
PLoS One; 2008 Apr; 3(4):e1952. PubMed ID: 18398475
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling.
Cai Q; Peng G; Bu L; Lin Y; Zhang L; Lustigmen S; Wang H
Vaccine; 2007 Jul; 25(28):5155-65. PubMed ID: 17548134
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.
Tamborrini M; Stoffel SA; Westerfeld N; Amacker M; Theisen M; Zurbriggen R; Pluschke G
Malar J; 2011 Dec; 10():359. PubMed ID: 22166048
[TBL] [Abstract][Full Text] [Related]
15. [Construction and expression of Plasmodium berghei chimeric protein in Pichia pastoris and its immunogenicity in mice].
Cao Y; Zhang DM; Pan WQ
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2008 Oct; 26(5):327-31. PubMed ID: 19157293
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and protective efficacy of Escherichia coli expressed Plasmodium falciparum merozoite surface protein-1(42) using human compatible adjuvants.
Sachdeva S; Mohmmed A; Dasaradhi PV; Crabb BS; Katyal A; Malhotra P; Chauhan VS
Vaccine; 2006 Mar; 24(12):2007-16. PubMed ID: 16377036
[TBL] [Abstract][Full Text] [Related]
17. Long term stability of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Montanide(®) ISA 720 and stabilized with glycine.
Zhu D; McClellan H; Dai W; Gebregeorgis E; Kidwell MA; Aebig J; Rausch KM; Martin LB; Ellis RD; Miller L; Wu Y
Vaccine; 2011 May; 29(20):3640-5. PubMed ID: 21440641
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of a recombinant malaria vaccine based on receptor binding domain of Plasmodium falciparum EBA-175.
Pattnaik P; Shakri AR; Singh S; Goel S; Mukherjee P; Chitnis CE
Vaccine; 2007 Jan; 25(5):806-13. PubMed ID: 17045706
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.
Devi YS; Mukherjee P; Yazdani SS; Shakri AR; Mazumdar S; Pandey S; Chitnis CE; Chauhan VS
Vaccine; 2007 Jul; 25(28):5166-74. PubMed ID: 17544179
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys.
Pichyangkul S; Tongtawe P; Kum-Arb U; Yongvanitchit K; Gettayacamin M; Hollingdale MR; Limsalakpetch A; Stewart VA; Lanar DE; Dutta S; Angov E; Ware LA; Bergmann-Leitner ES; House B; Voss G; Dubois MC; Cohen JD; Fukuda MM; Heppner DG; Miller RS
Vaccine; 2009 Dec; 28(2):452-62. PubMed ID: 19857448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
